An interventional study of Percutaneous intervention (stent) for PA stenosis in Transposition of Great Vessels, Tetralogy of Fallot and Truncus Arteriosus, sponsored by UMC Utrecht. Recruiting at 4 sites in Netherlands. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by UMC Utrecht · Not applicable, Interventional, and Treatment
The goal of this randomized controlled trial is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA.
The main question[s] it aims to answer are:
The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.
Participants will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.
Researchers will compare the difference in VO2 max (% predicted) between the interventional group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo a percutaneous intervention for a PA stenosis) and the control group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo conservative management)
Rationale: Postoperative survival of patients with dextro transposition of the great arteries (d-TGA), Tetralogy of Fallot (ToF) and Truncus Arteriosus (TA) has increased over the last decades due to advances in operative techniques and perioperative care. Despite postoperative survival has increased, morbidity of these patients increases during long-term follow-up with a high need for reinterventions. Right ventricular outflow tract (RVOT) obstructions are the most common indication for a reintervention and percutaneous branch pulmonary artery (PA) interventions account for a significant number of these reinterventions. However, the effects of percutaneous branch PA interventions on exercise capacity, RV function and RV adaptation of patients with d-TGA, ToF and TA remains largely unknown. In addition, there is no consensus about the optimal timing for percutaneous interventions for branch PA stenosis in international guidelines.
Objective: The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.
Study design: This is a multicenter randomized controlled trial. Patients will be included from the following Dutch interventional centers for congenital heart disease: UMC Utrecht/WKZ (sponsor), LUMC/AUMC and Erasmus MC. During this trial there will be two groups: 1. a group of patients with d-TGA, ToF and TA who will undergo a percutaneous intervention for a branch PA stenosis according to standard care (intervention group) and 2. a group of patients with d-TGA, ToF and TA with a similar degree of pulmonary stenosis as group 1 (class IIa indication) who will undergo conservative management for a branch PA stenosis according to standard care (control group). If necessary, the control group will be able to undergo a percutaneous intervention for branch PA stenosis after the examinations at approximately 6 months follow-up, or sooner in case of symptoms. Patients from both groups will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.
Study population: d-TGA post ASO, ToF or TA patients ≥8 years old will be included if they have a class IIa indication for a percutaneous intervention for branch PA stenosis according to the international guidelines. Patients will be excluded if they contraindications for one of the examinations.
Main study parameters/endpoints: the difference in VO2 max (% predicted) as parameter for exercise capacity between the interventional and control group.
44 studies on the registry are indexed under Transposition of Great Vessels; 9 are open to participants now.
This study's planned enrollment of 56 is close to the median of 56 across 21 interventional studies indexed under Transposition of Great Vessels.
Browse Transposition of Great Vessels studies →UMC Utrecht is the lead sponsor of 364 studies on the registry; 82 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
Exclusion Criteria:
One or more of the following inclusion criteria:
Persistent decreased RV function (based on gold standard CMR)
Isolated bifurcation stenosis:
Reduced lung perfusion or decreased objective exercise capacity (based of gold standard VO2 max during CPET)
Percutaneous intervention for PA stenosis
Procedure: Percutaneous intervention (stent) for PA stenosis
Conservative management (percutaneous intervention for PA stenosis 6 months postponed)
Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
Change from baseline VO2max as percentage of predicted at 6 months as indication of exercise capacity
using cardiopulmonary exercise test on a treadmill
Time frame: change between baseline and 6 months follow-up
Technical success using invasive right ventricular and pulmonary artery pressures and gradients
Technical success of the intervention using invasive right ventricular and pulmonary artery pressures and gradients
Time frame: after the intervention, an average of 1 month after baseline
Peak workload (W)
using cardiopulmonary exercise test on a treadmill
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
Peak workload (% predicted)
using cardiopulmonary exercise test on a treadmill
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
O2 pulse (ml)
using cardiopulmonary exercise test on a treadmill
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
O2 pulse (% predicted)
using cardiopulmonary exercise test on a treadmill
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
VE/VCO2 slope
using cardiopulmonary exercise test on a treadmill
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
Right ventricular ejection fraction (%)
using CMR
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV strain (%)
using speckle tracking echocardiography and CMR feature tracking
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV fractional area change (%)
using echocardiography
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV pressure (mmHg)
using echocardiography (TI gradient)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV end-systolic elastance
using pressure-volume analysis
Time frame: before and after the intervention, an average of 1 month after baseline
RV end systolic volume (ml and ml/m2)
using CMR
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV end diastolic volume (ml and ml/m2)
using CMR
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV functional reserve
RVEF dobutamine - RVEF rest using a low dose dobutamine stress MRI
Time frame: at baseline and 6 months follow-up in the interventional group from UMC Utrecht and Erasmus MC
RV mass (g and g/m2)
using CMR
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
Right ventricular pulmonary arterial (RV-PA) coupling
using pressure-volume analysis
Time frame: before and after the intervention, an average of 1 month after baseline
Lung perfusion (%)
using CMR
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
Quality of Life (QoL) in 4 domains: health and related activities, emotional, social and school/work
using PedsQL questionnaire
Time frame: at baseline and 2 weeks follow-up
Plan to share: No — We will publish the results in peer-reviewed journals and present them at meetings and conferences. As the data is privacy-sensitive, the database will not be publically available. A request for a collaboration can be made via DataverseNL.
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Dec 2027, 56 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Transposition of Great Vessels →